Israel’s First Pure-Play Cannabis Enterprise

Isracann, Israel’s first pure-play cannabis firm, is focused on becoming a premier, low-cost cannabis producer. Isracann is fully funded to execute on over 230,000 sq ft of hybrid greenhouse.

The company is targeting undersupplied domestic demand combined with an immense international market opportunity through Israel’s new medical cannabis export framework for 2020.

Business Model: Four Pillars

Isracann believes in four verticals to leverage its expertise and scale its business

Cultivation

  • Architectural design reviewed by Security consultant and Best Practices consultant.
  • Designs submission to Israeli Land Authority.
  • Application submission to use land as a joint venture.
  • Land inspection by the Israeli Land Authority.
  • Specific Genetics offtake program designed to provide highest quality gene material within Israel.
  • EU GMP certified packing/drying facility targets highest quality product for domestic and export markets.

Manufacturing

  • ISL/EU GMP Manufacturing Processes
  • Strategic LOI with Israeli manufacturer defines a clear path to in-country revenue.
  • Sourcing additional capacity to meet future demand.
  • Low-cost production (est. $0.40/gram).
  • IMC-GAP/GSP certified for export compliance.
  • Production layout offers excellent modularity for irrigation, electrical distribution and maintenance.
  • Ideal climate for industrial scale cultivation.

Distribution

  • Israel’s massive domestic undersupply drives regional demand.
  • Proximity to the EU allows efficient export under new legislation (January 2019).
  • Strategic distribution partner provides practical intermediate multinational trans-shipment entry point.
  • Product access to Germany, United Kingdom, Poland & Denmark.
  • Existing product lines provide access to domestic and export markets.

Branding

  • Israel is recognized worldwide as a center for excellence in agronomy, research, genetics, manufacturing and quality assurance.
  • Regional expertise allows for branding differentiation that resonates across the globe.
  • Brand positioning will focus on high quality “made in Israel Cannabis.”
  • Israeli brand will aid positioning of new commercial formulations.
  • Build out of Cannabis/CBD product lines will emphasize regional attributes and quality.

The Team

President & CEO Darryl Jones Darryl Jones has over 15 years of capital market experience with a well-established financial network. Prior to joining Isracann in 2018, Mr. Jones was an investment advisor with PI Financial…
Read More
COO Israel Moseson Mr. Moseson has been involved in the cannabis sector for over 5 years in Israel and is responsible for in-country operations. Prior to entering the cannabis industry, Mr. Moseson specialized…
Read More
Director Irit Arbel , Ph.D. Dr. Arbel brings significant senior multidisciplinary biopharma experience to Isracann’s board. She has served as Director and President of Brainstorm Cell Therapeutics, and as Executive Vice President of Research and…
Read More
Advisory Board Member Brett Allan Mr. Allan has over 10 years of investment and capital markets experience and is currently founder, President and CEO of Apex Capital. Apex provides investor relations, PR and corporate finance…
Read More
Strategic Advisor Nitin Kaushal Mr. Kaushal is a managing director with PwC in the Corporate Finance Practice in Toronto with 25 years experience in the healthcare industry. Mr. Kaushal has participated in capital market…
Read More
Advisory Board Member Mathew Christopherson Mr. Christopherson has over 10 years of experience within the cannabis space. Previously he was VP of Business Development and a Partner at Keirton Inc., a company that provides growers…
Read More
Advisory Board Member Justin Cooper Mr. Cooper is Co-Owner of Green Planet Wholesale, the largest privately owned hydroponics chain in Canada. For +25 years he has built manufacturing, wholesale, & retail locations servicing some of…
Read More